SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT2) inhibitors wereinitially developed to manage blood sugar levels in individuals with type 2 diabetes mellitus (T2DM) [2],but they have demonstrated heart-protective effects beyond glucose control, including improved heart function, reduced oxidative stress, andless cardiac inflammation and scarring [3].